Boston Scientific (NYSE:BSX) FY Conference January 13, 2026 12:00 PM ET Company ParticipantsMike Mahoney - Chairman and CEOKen Stein - Senior VP and Chief Medical OfficerJon Monson - EVP and CFOConference Call ParticipantsRobbie Marcus - Medtech Senior AnalystRobbie MarcusHello, everyone. Welcome. I'm Robbie Marcus, the MedTech Analyst at JPMorgan. Really happy to host Boston Scientific. We have Mike Mahoney, CEO, Jon Monson, CFO, and Dr. Stein, Chief Medical Officer. We're going to do a fireside chat here. ...

Core Viewpoint - Boston Scientific (BSX) is showing potential as a stock pick due to its recent technical performance and positive earnings estimate revisions [1][3]. Technical Analysis - BSX has surpassed the 50-day moving average, indicating a short-term bullish trend [1]. - The stock has increased by 5.7% over the past four weeks, suggesting upward momentum [2]. Earnings Estimates - There have been no downward revisions for BSX's earnings estimates in the past two months, with one upward revision noted [3]. - The consensus estimate for BSX has also increased, reinforcing the bullish outlook for the stock [3]. Market Position - BSX is currently rated as a Zacks Rank 2 (Buy), indicating strong potential for continued growth [2].

Company Performance - Boston Scientific (BSX) closed at $97.79, with a gain of +2.42%, outperforming the S&P 500's gain of 0.62% on the same day [1] - Prior to this trading session, BSX shares had increased by 1.75%, contrasting with the Medical sector's decline of 1.22% and the S&P 500's gain of 0.59% [1] Earnings Projections - The company is expected to release its earnings on February 4, 2026, with projected EPS of $0.78, reflecting an 11.43% increase year-over-year [2] - Revenue for the upcoming quarter is anticipated to be $5.27 billion, indicating a 15.44% increase compared to the same quarter last year [2] Fiscal Year Estimates - For the entire fiscal year, earnings are projected at $3.04 per share, representing a +21.12% change from the previous year, while revenue is estimated at $20.06 billion, showing no change [3] - Recent analyst estimate revisions for Boston Scientific suggest positive short-term business trends, which are typically seen as favorable for the business outlook [3] Stock Valuation - Boston Scientific is currently trading at a Forward P/E ratio of 27.65, which is higher than the industry average of 19.35 [6] - The company has a PEG ratio of 1.69, compared to the Medical - Products industry's average PEG ratio of 1.71 [6] Industry Ranking - The Medical - Products industry, part of the Medical sector, has a Zacks Industry Rank of 162, placing it in the bottom 34% of over 250 industries [7] - The Zacks Industry Rank indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]

Core Insights - Boston Scientific's Cardiovascular segment operates in a $50 billion market, projected to grow nearly 9% from 2026 to 2028, with expectations to exceed 10% average organic revenue growth [1] - The Electrophysiology (EP) business is anticipated to grow approximately 15% over the long-range plan, driven by market share gains and expansion into new areas [1][8] - The WATCHMAN device is the leading percutaneous left atrial appendage closure (LAAC) device globally, with a long-term growth outlook of over 20% contingent on trial outcomes [2][8] - The CRM DX business is expected to grow about 4% over the long-range plan, supported by recent investments and new product launches [3] - The Interventional Cardiology Therapies (ICTx) segment is projected to achieve 10% growth, particularly in emerging markets [4][8] - The Peripheral Interventions, Interventional Oncology, and Embolics businesses collectively represent a $11 billion market, with expected growth around 7% [4] Competitive Landscape - Medtronic's Diabetes business is preparing for an IPO, while its Hugo robotic-assisted surgery system has received FDA approval for urologic procedures [5] - Johnson & Johnson has acquired Halda Therapeutics for $3.05 billion, enhancing its portfolio in prostate cancer therapies [6] Financial Performance - Boston Scientific shares have increased by 7.5% over the past year, outperforming the industry average of 1.7% [7] - The company's forward five-year Price-to-Earnings (P/E) ratio stands at 27.81, above both its median and the industry average [9] Earnings Estimates - Current earnings estimates for Boston Scientific indicate a projected earnings per share of $3.04 for the year ending December 2025, increasing to $3.45 for December 2026 [11]

Core Insights - Boston Scientific (BSX) and Resmed (RMD) are significant players in the global medical devices market, with market capitalizations of $142.4 billion and $35.72 billion, respectively [2] - The medical devices market is projected to grow at nearly 7% CAGR from 2025 to 2030, prompting an evaluation of investment opportunities in both companies [3] Boston Scientific Overview - Boston Scientific is experiencing strong performance in its Cardiovascular and MedSurg segments, with expectations for above-market growth through 2025-2026 [4] - The WATCHMAN device is a leading product in percutaneous left atrial appendage closure (LAAC), with a projected market expansion of approximately 20% in the coming years [5] - The company is gaining market share in electrophysiology, particularly with the FARAPULSE Pulsed Field Ablation System, which received FDA approval for expanded use in July 2025 [6] - Recent acquisitions, including Intera Oncology and Elutia's BioEnvelope business, support Boston Scientific's growth strategy and expansion into high-growth areas [7] - Emerging markets accounted for 15% of Boston Scientific's consolidated net sales in the first nine months of 2025, indicating significant long-term growth potential [8] Resmed Overview - Resmed is witnessing strong demand for its mask portfolio, including the AirFit and AirTouch ranges, and is focusing on direct-to-consumer markets in regions like China and India [9] - The company has launched new variants of its AirTouch F30i mask and continues to see strong sales from its AirSense device platforms [9] - Resmed is advancing AI integration in its digital health products, including the launch of the personal sleep health digital assistant, Dawn, in the U.S. [11] - The company is optimizing operations to improve gross margins and has made acquisitions like Somnoware and Ectosense to support its 2030 growth strategy [12] Financial Estimates and Performance - The Zacks Consensus Estimate for Boston Scientific's 2025 EPS indicates a year-over-year increase of 21.1% to $3.04, with a slight upward revision in the last 60 days [13] - Resmed's fiscal 2026 EPS consensus estimate of $10.84 reflects a 13.5% improvement over 2025, with a 3.3% increase in estimates over the past 60 days [15] - In the last 12 months, BSX shares have increased by 6.8%, while RMD shares have risen by 5.8% [16] Investment Considerations - Boston Scientific is highlighted for its divisional strength, ongoing momentum with the WATCHMAN device, and strategic acquisitions in high-growth markets [18] - Resmed remains focused on innovation and strong demand for its products, but Boston Scientific is currently viewed as the more attractive investment option based on recent performance [18] - Boston Scientific holds a Zacks Rank 2 (Buy), while Resmed has a Zacks Rank 3 (Hold) [20]

Core Viewpoint - The chronic pain medical device market in China is expected to grow significantly, driven by factors such as an aging population, increasing prevalence of chronic diseases, improved policy and insurance environments, and technological advancements [5][11]. Market Overview - The sales revenue of China's chronic pain medical device market is projected to reach $386.51 million in 2024 and $720 million by 2031, with a compound annual growth rate (CAGR) of 9.29% from 2025 to 2031 [5]. Industry Concentration and Competition - Major players in the Chinese market include Medtronic, Xiangyu Medical, Boston Scientific, Abbott, and OMRON, with the top three companies holding approximately 55.9% of the market share in 2024 [9]. Development Drivers - The market is primarily driven by three factors: 1. Aging population and high incidence of chronic diseases, leading to increased demand for pain management devices [11]. 2. Improved policies and insurance frameworks that facilitate multi-disciplinary management of pain [11]. 3. Technological advancements, including wearable devices and smart pain management solutions, enhancing personalized treatment options [11]. Challenges - The industry faces several challenges: 1. Fragmented market competition, with international brands dominating high-end segments while domestic companies focus on mid to low-end markets [11]. 2. High regulatory and clinical entry barriers, increasing pressure on small and medium enterprises [11]. 3. Incomplete payment systems, limiting the adoption of certain pain management devices in primary care and home settings [11]. 4. Insufficient awareness among patients and doctors regarding non-drug pain treatments, necessitating further market education [11]. Future Trends - The market is expected to trend towards smart and home-based solutions, with advancements in AI, big data, and IoT enabling remote monitoring and personalized treatment [12]. - The demand for portable and easy-to-use devices is rising, shifting the market focus from hospital-centric to a dual "hospital + home" model [12]. - Domestic innovation and international expansion are anticipated to be key trends, with policies supporting local manufacturers and new market opportunities emerging in regions like Southeast Asia and the Middle East [12]. Policy Framework - The Chinese government emphasizes the development of the medical device sector through various policies aimed at enhancing innovation and competitiveness [13][15]. - Key policies include the "Healthy China 2030" initiative and the "Made in China 2025" plan, which focus on improving the innovation capabilities of medical devices [13][15]. Supply Chain Analysis - The supply chain for chronic pain medical devices includes upstream raw material suppliers such as Nippon Steel and SABIC, and downstream markets comprising hospitals, home care, and rehabilitation centers [19][20]. - The hospital sector is the primary market for high-end devices, while the home care segment is rapidly growing, particularly for non-invasive devices like TENS units [20].

Core Viewpoint - Boston Scientific (BSX) is viewed positively for both short-term and long-term prospects, being considered one of the best investment ideas in the medical devices sector [1]. Company Analysis - The company operates within the medical devices industry, which is characterized by significant growth potential and innovation [1]. - Boston Scientific is recognized for its strong fundamentals and ability to uncover hidden value, making it an attractive option for investors [1]. Market Context - The medical devices sector is experiencing robust demand, driven by advancements in technology and an increasing focus on healthcare solutions [1]. - Investment opportunities in this sector are expected to grow, particularly for companies like Boston Scientific that demonstrate strong performance and strategic positioning [1].

Core Viewpoint - Boston Scientific (BSX) is viewed positively for both short-term and long-term investment prospects, being considered one of the best investment ideas in the medical devices sector [1]. Company Analysis - The company operates within the medical devices industry, which is characterized by significant growth potential and innovation [1]. - Boston Scientific is recognized for its strong fundamentals and ability to uncover hidden value, making it an attractive option for investors [1]. Market Context - The medical devices sector is experiencing robust demand, driven by advancements in technology and an increasing focus on healthcare solutions [1]. - Investment opportunities in this sector are expected to continue growing, positioning companies like Boston Scientific favorably in the market [1].

Core Viewpoint - Valuation may not be significant in the short term for well-managed companies with above-average growth, but it eventually becomes important, as evidenced by Boston Scientific Corporation in 2025 [1] Group 1 - The article emphasizes that valuation matters over time, particularly for companies like Boston Scientific Corporation [1]

Core Insights - Boston Scientific's Endoscopy business is a vital part of its MedSurg segment, focusing on innovative, less invasive technologies for gastrointestinal and pulmonary conditions, with net sales of $2.16 billion in the first nine months of 2025, accounting for 15% of total sales [2][9] - The endoscopy market is valued at $8 billion and is projected to grow at approximately 6% from 2026 to 2028, with Boston Scientific aiming to exceed this growth while improving operating margins [2][9] Business Segments - The Endoscopy portfolio is divided into four key areas, including pancreaticobiliary, which features products like SpyGlass and EXALT D, with plans to launch a capital platform next year to enhance imaging technologies using AI [3] - Endoluminal surgery is another significant area, with innovations such as MANTIS and OverStitch, facilitating the transition from traditional operating rooms to endoscopic therapies through improved tools [4] - The company is also focusing on Endobariatrics, offering minimally invasive weight loss solutions through the Endura Weight Loss Solutions, targeting the obesity market [5] Market Performance - Boston Scientific's shares have increased by 5.5% over the past year, outperforming the industry average increase of 0.1% [8] - The stock is currently trading at a forward five-year Price-to-Earnings (P/E) ratio of 27.90, which is above both its median and the industry average [10] Earnings Estimates - Earnings estimates for Boston Scientific are trending upward, with the current quarter estimate at $0.78 and the next year estimate at $3.45 [11][12]